Orpha Labs AG Announces the Initiation of a Phase III Trial Evaluating ORL-101 for Treatment of Leukocyte Adhesion Deficiency Type II
 
Orpha Labs AG is working with investigators to switch patients from a compassionate use study initiated last year to this Phase III study.

Feb 23, 2022, 08:00 ET

Orpha Labs AG Initiates Compassionate Use Program for ORL-101 in Leukocyte Adhesion Deficiency Type II (LAD-II

First Patient to Receive ORL-101 in Israel This Week

Feb 08, 2021, 02:00 ET